ArticleChronic obstructive pulmonary diseases (Miami, Fla.)2020
Design of the Redefining Therapy in Early COPD Study.
Article in Chronic obstructive pulmonary diseases (Miami, Fla.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 16 citations in OpenAlex.
- Association Between Non-obstructive Chronic Bronchitis and Incident Chronic Obstructive Pulmonary Disease and All-Cause Mortality: A Systematic Review and Meta-Analysis.Frontiers in medicine · 2021Pooled it
- Efficacy and safety of ensifentrine in treatment of COPD: a systematic review and meta-analysis of clinical trials.Therapeutic advances in respiratory diseasePooled it
- Impact of the Population Medicine Multimorbidity Intervention in Xishui County (POPMIX) on People at High Risk for Chronic Obstructive Pulmonary Disease Who Experience Mental Health Symptoms: Protocol for the POPMIX-MH Cluster Randomized Controlled Trial.JMIR research protocols · 2026Trial
- Bronchodilators in Tobacco-Exposed Persons with Symptoms and Preserved Lung Function.The New England journal of medicine · 2022Trial
- Design of the SPIROMICS Study of Early COPD Progression: SOURCE Study.Chronic obstructive pulmonary diseases (Miami, Fla.) · 2024Article
- Clinical features and 1-year outcomes of variable obstruction in participants with preserved spirometry: results from the ECOPD study in China.BMJ open respiratory research · 2024Article
- Addressing the Use of the CAPTURE (a Chronic Obstructive Pulmonary Disease Screening Tool) in Chronic Obstructive Pulmonary Disease Treatment Decisions.American journal of respiratory and critical care medicine · 2023Article
- Observational
- Small airway function measured using forced expiratory flow between 25% and 75% of vital capacity and its relationship to airflow limitation in symptomatic ever-smokers: a cross-sectional study.BMJ open respiratory research · 2022Article
- Journal Club-Respiratory Impairment With A Preserved Spirometric Ratio.Chronic obstructive pulmonary diseases (Miami, Fla.) · 2022Article
- Catching "Early" COPD - The Diagnostic Conundrum.International journal of chronic obstructive pulmonary diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
Redefining Therapy in Early COPD (RETHINC) is a 12-week multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy and safety of indacaterol/glycopyrrolate 27.5/15.6 mcg inhaled twice daily in symptomatic current and former smokers with respiratory symptoms as defined by COPD Assessment Test (CAT) score ≥ 10 despite preserved spirometry defined by post-bronchodilator forced expiratory volume in 1 second (FEV
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.